Also, a large recent study has shown that semaglutide is associated with significantly reduced risk of first-time AD diagnosis in T2D patients when compared with those prescribed other antidiabetic medications, including insulin and other GLP1 analogs. This evidence concerns the gene GLP1R and Alzheimer disease.